Nutriband (NASDAQ:NTRB) Stock Price Up 1.7% – Here’s Why

Nutriband Inc. (NASDAQ:NTRB)’s share price traded up 1.7% on Thursday . The company traded as high as $7.86 and last traded at $7.83. 21,051 shares traded hands during trading, a decline of 74% from the average session volume of 80,500 shares. The stock had previously closed at $7.70.

Nutriband Stock Performance

The firm has a market cap of $87.30 million, a PE ratio of -8.70 and a beta of 1.11. The stock has a 50-day moving average price of $6.50 and a 200 day moving average price of $6.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.71 and a quick ratio of 3.48.

Nutriband (NASDAQ:NTRB) last issued its quarterly earnings results on Friday, May 30th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.71 million. Nutriband had a negative return on equity of 68.25% and a negative net margin of 415.93%. Research analysts forecast that Nutriband Inc. will post -0.6 earnings per share for the current year.

Institutional Trading of Nutriband

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in Nutriband by 7.5% during the fourth quarter. Geode Capital Management LLC now owns 62,435 shares of the company’s stock worth $294,000 after buying an additional 4,372 shares during the period. Haven Private LLC acquired a new position in shares of Nutriband during the 4th quarter valued at $54,000. Finally, US Bancorp DE purchased a new stake in Nutriband during the 1st quarter worth $29,000. Institutional investors and hedge funds own 19.70% of the company’s stock.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.